KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Cash and Cash Equivalents

Last Annual Value

98.05M

3-Year CAGR

218%

5-Year CAGR

-4%

10-Year CAGR

-2%

KT

Kalaris Therapeutics Inc Competitors Analysis of Cash and Cash Equivalents

KLRS · NASDAQ
CompanyCash and Cash Equivalents
CAGR 3Y
CAGR 5Y
CAGR 10Y
98.05M
213.9%-13.4%N/A 
13.15M
-21.4%-41.2%-12.8%
26.70M
-20.7%-30.2%N/A
54.19M
-24.4%-10.1%N/A
66.00M
65.9%5.9%N/A
41.72M
-33.3%1.2%N/A
60.65M
-6.8%12.1%-12.2%
16.37M
-9.9%-46.2%N/A
81.54M
34.5%-3.1%N/A
48.91M
-20.2%2.7%N/A
45.95M
71.8%-9.9%28.0%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7